|
Compound (rutin with other therapeutically drugs) | Mechanism | Cancer cell line | Reference |
|
Apigenin, tamoxifen | Induce apoptosis through a p53-dependent pathway | Breast cancer cell line (MCF-7) | [48] |
Cisplatin, isoquercetin | Inducing toxicity, could decrees cell count percentage in G0/G1, S, and G2/M phases in addition to increase it in sub G0 phase in comparison with the single doses | Gastric cancer | [49] |
Hyperoside | Increase the expression of regulator positive apoptosis such as Bax, Caspase 3, 8, 9 | Colon cancer cells (HT-29) | [50] |
5-FU | Increase of p53 gene expression and decreases Bcl-2 protein expression | Prostate cancer cell (PC3) | [21] |
Oxaliplatin | Induced apoptosis may be associated with the activation of the p38/caspase signal pathway | SGC-7901 gastric cancer cell line | [51] |
Orlistat | Cytotoxic effects and promoting apoptosis | Breast cancer (MCF-7) and pancreatic cancer cell line (PANC-1) | [5] |
Oxidovanadium(IV) | Inhibit superoxide, hydroxyl radicals and improved the antioxidant activity | Lung cancer A549 cell line | [52] |
5-FU and oxaliplatin | Antiproliferative effect and reduce possible adverse effects of these drugs | Caco-2 cancer cell line | [53] |
Zein-co-acrylic acid hybrid hydrogels loaded 5-fluorouracil | Enhanced anticancer efficacy | MDA-MB-231 and MCF-7 breast cancer cell lines | [54, 55] |
Doxorubicin (DOX) | Anticancer, protective effects | Human neuroblastoma cell line (IMR32) | [56] |
|